Neurology Specific Literature Search   
 
[home][thesaurus]
    

Differential
(Click to cross reference)
advances in neurology
adverse drug reaction
antiviral agents
asymptomatic
compliance
complications
highly active antiretroviral therapy
human immunodeficiency virus type 1
human immunodeficiency virus type 1, prophylaxis
preexposure prophylaxis
prevention of neurologic disorders
safety
sexually transmitted disease
treatment of neurologic disorder
viral infection
Showing articles 700 to 750 of 3067 << Previous Next >>

Association Between Clinical Conversion to Multiple Sclerosis in Radiologically Isolated Syndrome and Magnetic Resonance Imaging, Cerebrospinal Fluid, and Visual Evoked Potential: Follow-Up of 70 Patients
Arch Neurol 66:841-846, Lebrun,C.,et al, 2009

A 70-Year-Old Woman with Shingles: Review of Herpes Zoster
JAMA 302:73-80,108, Whitley,R.J., 2009

Treating Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation
NEJM 360:2730-2741, Pui,C.-H.,et al, 2009

Acute Disseminated Encephalomyelitis Following Vacicnation Against Human Papilloma Virus
Neurol 72:2132-2133, Wildemann,B.,et al, 2009

The Risks and Costs of Multiple-Generic Substitution of Topiramate
Neurol 72:2122-2129, Duh,M.S.,et al, 2009

Cyclophosphamide Therapy in Pediatric Multiple Sclerosis
Neurol 72:2076-2082,2064, Makhani,N.,et al, 2009

Efficacy of Treatment of MS with IFN B-1b or Glatiramer Acetate by Monthly Brain MRI in the BECOME Study
Neurol 72:1976-1983,1972, Cadavid,D.,et al, 2009

Effectiveness of Thigh-Length Graduated Compression Stockings to Reduce the Risk of Deep Vein Thrombosis After Stroke (CLOTS Trial 1): A Multicentre, Randomised Controlled Trial
Lancet 373:1958-1965,1923, The CLOTS Trial Collaboration, 2009

Risk of Dementia and AD with Prior Exposure to NSAIDs in an Elderly Community-Based Cohort
Neurol 72:1899-1905,1884, Breitner,J.C.S.,et al, 2009

Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients with Atrial Fibrillation: A Randomised Non-Inferiority Trial
Lancet 374:534-542,504, Holmes,D.R.,et al, 2009

Antithrombotic Management of Patients with Prosthetic Heart Valves: Current Evidence and Future Trends
Lancet 374:565-576, Sun,J.C.J.,et al, 2009

Who Is Ineligible for Warfarin in Atrial Fibrillation?
Lancet 374:510-511, Verheugt,F.W.A., 2009

Lamotrigine Kinetics Within the Menstrual Cycle, After Menopause, and with Oral Contraceptives
Neurol 73:1388-1393, Wegner,I.,et al, 2009

Interventions in the Management of Serum Lipids for Preventing Stroke Recurrence
Stroke 40:e622-e623, Manktelow,B. &Potter,J., 2009

Real-Life Impact of Early Interferon� Therapy in Relapsing Multiple Sclerosis
Ann Neurol 66:513-520, Trojano,M.,et al, 2009

Chitosan May Decrease Serum Valproate and Increase Risk of Seizure Reappearance
BMJ 339:a2163, Striano,P.,et al, 2009

Primary Central Nervous System Lymphoma in a Patient Treated with Natalizumab
Ann Neurol 66:403-406, 261, 262, Schweikert,A.,et al, 2009

Seizure Relapse and Development of Drug Resistance Following Long-Term Seizure Remission
Arch Neurol 66:1233-1239, Schiller,Y., 2009

Medical (Nonsurgical) Intervention Alone Is Now Best for Prevention of Stroke Associated With Asymptomatic Severe Carotid Stenosis
Stroke 40:e573-e583, Abbott,A., 2009

Incidental Findings on Brain Magnetic Resonance Imaging: Systematic Review and Meta-analysis
BMJ 339:547-550, 522, Morris,Z.,et al, 2009

Diagnosis and Management of Neuropathic Pain
BMJ 339:391-395, Freynhagen,R. &Bennett,M.I., 2009

Screening for Intracranial Aneurysms in ADPKD: A More Accurate Risk Assignment Model Is Needed
BMJ 339:706-707, Ong,A., 2009

The Present Efficacy of Multiple Sclerosis Therapeutics
Neurol 73:984-990, Klawiter,E.,et al, 2009

Severe Cardiac Failure in a Patient with Multiple Sclerosis Following Low-Dose Mitoxantrone Treatment
Neurol 73:991-993, D�rr,J.,et al, 2009

A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinsons Disease
NEJM 361:1268-1278, 1304, Olanow,C.,et al, 2009

Dabigatran Versus Warfarin in Patients with Atrial Fibrillation
NEJM 361:1139-1151, 1200, Connolly,S.,et al, 2009

Practice Parameter: Evaluation of the Child with Microcephaly (An Evidence-Based Review): Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society
Neurol 73:887-897, Ashwal,S.,et al, 2009

Cranial Dural Arteriovenous Fistula: Diagnosis and Classification with Time-Resolved MR Angiography at 3T
AJNR 30:1546-1551, Farb,R.I.,et al, 2009

Should I Have an H1N1 Flu Vaccination After Guillain-Barr�
BMJ 339:635, Price,L., 2009

Progressive Multifocal Leukoencephalopathy After Natalizumab Monotherapy
NEJM 361:1081-1087, Linda,H.,et al, 2009

Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab
NEJM 361:1075-1080, Wenning,W.,et al, 2009

Angiotensin Receptor Blockers Should Be Regarded as First-Line Drugs for Stroke Prevention in Both Primary and Secondary Prevention Settings: No
Stroke 40:3161-3162, 3163, Strauss,M. &Hall,A., 2009

Angiotensin Receptor Blockers Should Be Regarded as First-Line Drugs for Stroke Prevention in Both Primary and Secondary Prevention Settings: Yes
Stroke 40:3159-3160, 3163, Hackam,D., 2009

DNA �-Amyloid1-42 Trimer Immunization for Alzheimer Disease in a Wild-Type Mouse Model
JAMA 302:1796-1802, Lambracht-Washington,D.,et al, 2009

High-Flow Oxygen for Treatment of Cluster Headache: A Randomized Trial
JAMA 302:2451-2457, 2502, Cohen,A.,et al, 2009

Autism
Lancet 374:1627-1638, Levy,S.,et al, 2009

The Value of Specifying Brand-Name Antiepileptic Drugs
Arch Neurol 66:1415-1416, 1418, Ng,Y., 2009

Generic Anticonvulsant Use in Children: Do We Have Evidence to Recommend Brand Formulations?
Arch Neurol 66:1417-1418, Hamiwka,L., 2009

Effect of Glatiramer Acetate on Conversion to Clinically Definite Multiple Sclerosis in Patients with Clinically Isolated Syndrome (PreCISe study): A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 374:1503-1511, 1475, Martinelli,G.,et al, 2009

Oral Fingolimod (FTY720) in Multiple Sclerosis: Two-Year Results of a Phase II Extension Study
Neurol 72:73-79, OConnor,P.,et al, 2009

Persistent Fainting After Implantation of a "Curative" Pacemaker
NEJM 360:88-89, Kasim,S.,et al, 2009

Intracerebral Haemorrhage
Lancet 373:1632-1644, Qureshi,A.I.,et al, 2009

Tumefactive Demyelination: An Approach to Diagnosis and Management
JNNP 84:1047-1053, Hardy, T.A. & Chataway, J., 2009

Melanoma Complicating Treatment with Natalizumab for Multiple Sclerosis
NEJM 358:647-648, Mullen,J.T.,et al, 2008

Statin Treatment and the Occurrence of Hemorrhagic Stroke in Patients With a History of Cerebrovascular Disease
Stroke 39:497-502, Vergouwen,M.D.I.,et al, 2008

Tension-Type Headache
BMJ 336:88-92, Loder,E. &Rizzoli,P., 2008

Botulinum Toxin Type A for the Treatment of Headache: Why We Say Yes
Arch Neurol 65:146-149,151, Ashkenazi,A. &Silberstein,S., 2008

Headache Therapy With Botulinum Toxin: Form Over Substance
Arch Neurol 65:149-151,151, Pakalnis,A. &Couch,J., 2008

Progressive Bone Deficit in Epilepsy
Neurol 70:170-176,166, Sheth,R.D.,et al, 2008

Mitoxantrone as Induction Treatment in aggressive Relapsing Remitting Multiple Sclerosis: Treatment Response Factors in a 5 Year Follow-up Observational Study of 100 Consecutive Patients
JNNP 79:52-56, Le Page,E.,et al, 2008



Showing articles 700 to 750 of 3067 << Previous Next >>